Russell Investments Group Ltd. Sells 20,499 Shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Russell Investments Group Ltd. reduced its stake in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) by 21.9% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 73,139 shares of the medical equipment provider's stock after selling 20,499 shares during the quarter. Russell Investments Group Ltd.'s holdings in Zimmer Biomet were worth $7,720,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Stonebridge Financial Group LLC acquired a new position in Zimmer Biomet during the 4th quarter worth $25,000. Kentucky Trust Co acquired a new stake in Zimmer Biomet in the fourth quarter worth about $39,000. OFI Invest Asset Management bought a new position in shares of Zimmer Biomet in the 4th quarter valued at about $40,000. SRS Capital Advisors Inc. grew its holdings in Zimmer Biomet by 146.9% during the 4th quarter. SRS Capital Advisors Inc. now owns 479 shares of the medical equipment provider's stock worth $51,000 after acquiring an additional 285 shares during the period. Finally, Atala Financial Inc acquired a new position in shares of Zimmer Biomet in the 4th quarter valued at $51,000. 88.89% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Zimmer Biomet

In other Zimmer Biomet news, SVP Lori Winkler sold 1,443 shares of the company's stock in a transaction on Wednesday, March 5th. The shares were sold at an average price of $104.40, for a total transaction of $150,649.20. Following the transaction, the senior vice president now owns 8,768 shares in the company, valued at approximately $915,379.20. This represents a 14.13 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. 0.95% of the stock is owned by insiders.

Zimmer Biomet Trading Up 1.0 %

NYSE ZBH traded up $0.96 during trading hours on Friday, hitting $97.90. 4,367,870 shares of the company's stock were exchanged, compared to its average volume of 1,650,696. The firm has a market cap of $19.37 billion, a price-to-earnings ratio of 22.00, a PEG ratio of 1.95 and a beta of 0.84. Zimmer Biomet Holdings, Inc. has a 1-year low of $96.58 and a 1-year high of $123.96. The stock has a 50-day simple moving average of $105.95 and a 200 day simple moving average of $106.78. The company has a current ratio of 1.91, a quick ratio of 0.99 and a debt-to-equity ratio of 0.43.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last issued its earnings results on Thursday, February 6th. The medical equipment provider reported $2.31 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.30 by $0.01. Zimmer Biomet had a net margin of 11.77% and a return on equity of 12.99%. During the same quarter last year, the firm earned $2.20 EPS. On average, equities analysts forecast that Zimmer Biomet Holdings, Inc. will post 8.22 EPS for the current fiscal year.

Zimmer Biomet Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, April 30th. Shareholders of record on Monday, March 31st will be paid a $0.24 dividend. The ex-dividend date of this dividend is Monday, March 31st. This represents a $0.96 dividend on an annualized basis and a yield of 0.98%. Zimmer Biomet's dividend payout ratio (DPR) is presently 21.57%.

Wall Street Analysts Forecast Growth

A number of equities analysts have issued reports on ZBH shares. Royal Bank of Canada reduced their target price on Zimmer Biomet from $130.00 to $125.00 and set an "outperform" rating on the stock in a report on Friday, February 7th. Stifel Nicolaus lifted their price target on shares of Zimmer Biomet from $130.00 to $138.00 and gave the stock a "buy" rating in a research report on Thursday, January 23rd. Truist Financial restated a "hold" rating and issued a $113.00 price objective (down previously from $118.00) on shares of Zimmer Biomet in a research report on Monday, February 10th. Raymond James dropped their price target on Zimmer Biomet from $126.00 to $119.00 and set an "outperform" rating on the stock in a research report on Friday, February 7th. Finally, BTIG Research reiterated a "buy" rating on shares of Zimmer Biomet in a research note on Monday. Two equities research analysts have rated the stock with a sell rating, eleven have given a hold rating and nine have assigned a buy rating to the company. According to MarketBeat.com, the stock has an average rating of "Hold" and a consensus price target of $124.15.

Zimmer Biomet Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.